Global Immune Cell Therapy Market
Global Immune Cell Therapy Market

Immune Cell Therapy Comprehensive Study by Application (Cancer, Autoimmune Disease, Chronic Inflammation), Forms (Nonspecific Immunotherapies, Cancer Vaccines), End User (Hospitals, Cancer Research Centers, Clinics) Players and Region - Global Market Outlook to 2027

Immune Cell Therapy Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Feb 2022 Edition 240 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Immune Cell Therapy Market?

Immune cell therapy is a new type of cancer treatment that boosts or enhances the body's immune system so that malignant cells can be targeted and destroyed more effectively. Immunotherapy, according to many experts, is the most promising new cancer treatment since the invention of chemotherapy. Nonspecific immunotherapies and cancer vaccines are examples of immune treatment. Nonspecific immunotherapies can be used in conjunction with or after other cancer treatments including chemotherapy and radiation therapy, or as a stand-alone therapy. Interferons, which activate the immune system to fight cancer, and interleukins, which enable the immune system manufacture cancer-fighting cells, are two common nonspecific immunotherapies. Cancer vaccines elicit an immune response to eliminate a specific protein by exposing the immune system to antigens.

The market study is being classified, by Application (Cancer, Autoimmune Disease and Chronic Inflammation) and major geographies with country level break-up.

Johnson & Johnson (United States), Pfizer Inc. (United States), Amgen Inc. (United States), Novartis AG (Switzerland), McKinsey & Company (United States), Bristol-Myers Squibb Company (United States), Gilead Sciences, Inc. (United States), Noile-Immune Biotech (Japan), Juno Therapeutics (United States) and Bluebird Bio (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Fate Therapeutics (United States), Legend Biotechnology Co., Ltd (United States) and Sorrento Therapeutics, Inc. (United States).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Immune Cell Therapy market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Immune Cell Therapy market by Type, Application and Region.

On the basis of geography, the market of Immune Cell Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Surge In Prevalence Of Cancer Among Global Population

Market Trend
  • Strong R&D Initiatives From Key Companies Are All Driving Immune Cell Therapy

Restraints
  • High Cost Associated With Immune Cell Therapy

Opportunities
  • Increase In Awareness About The New Approach To Treat Cancer Leads To Increase In Demand For Immune Cell Therapy
  • Government Favorable Incentives For Cancer Treatment

Challenges
  • Challenges To Develop Immune Cell Therapy Products





Key Target Audience
Immune Cell Therapy, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the Immune Cell Therapy Market?
"Surge In Prevalence Of Cancer Among Global Population" is seen as one of major growth factors of Immune Cell Therapy Market in years to come.

2. Can we have customized study for Immune Cell Therapy Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. Which region will lead the Global Immune Cell Therapy Market?
United States will lead Immune Cell Therapy Market in coming years.
Report Objectives / Segmentation Covered
By Application
  • Cancer
  • Autoimmune Disease
  • Chronic Inflammation
By Forms
  • Nonspecific Immunotherapies
  • Cancer Vaccines

By End User
  • Hospitals
  • Cancer Research Centers
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surge In Prevalence Of Cancer Among Global Population
    • 3.3. Market Challenges
      • 3.3.1. Challenges To Develop Immune Cell Therapy Products
    • 3.4. Market Trends
      • 3.4.1. Strong R&D Initiatives From Key Companies Are All Driving Immune Cell Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immune Cell Therapy, by Application, Forms, End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Immune Cell Therapy (Value)
      • 5.2.1. Global Immune Cell Therapy by: Application (Value)
        • 5.2.1.1. Cancer
        • 5.2.1.2. Autoimmune Disease
        • 5.2.1.3. Chronic Inflammation
      • 5.2.2. Global Immune Cell Therapy by: Forms (Value)
        • 5.2.2.1. Nonspecific Immunotherapies
        • 5.2.2.2. Cancer Vaccines
      • 5.2.3. Global Immune Cell Therapy by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Cancer Research Centers
        • 5.2.3.3. Clinics
      • 5.2.4. Global Immune Cell Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Immune Cell Therapy (Price)
  • 6. Immune Cell Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. McKinsey & Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Gilead Sciences, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Noile-Immune Biotech (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Juno Therapeutics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bluebird Bio (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Immune Cell Therapy Sale, by Application, Forms, End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Immune Cell Therapy (Value)
      • 7.2.1. Global Immune Cell Therapy by: Application (Value)
        • 7.2.1.1. Cancer
        • 7.2.1.2. Autoimmune Disease
        • 7.2.1.3. Chronic Inflammation
      • 7.2.2. Global Immune Cell Therapy by: Forms (Value)
        • 7.2.2.1. Nonspecific Immunotherapies
        • 7.2.2.2. Cancer Vaccines
      • 7.2.3. Global Immune Cell Therapy by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Cancer Research Centers
        • 7.2.3.3. Clinics
      • 7.2.4. Global Immune Cell Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Immune Cell Therapy (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immune Cell Therapy: by Application(USD Million)
  • Table 2. Immune Cell Therapy Cancer , by Region USD Million (2016-2021)
  • Table 3. Immune Cell Therapy Autoimmune Disease , by Region USD Million (2016-2021)
  • Table 4. Immune Cell Therapy Chronic Inflammation , by Region USD Million (2016-2021)
  • Table 5. Immune Cell Therapy: by Forms(USD Million)
  • Table 6. Immune Cell Therapy Nonspecific Immunotherapies , by Region USD Million (2016-2021)
  • Table 7. Immune Cell Therapy Cancer Vaccines , by Region USD Million (2016-2021)
  • Table 8. Immune Cell Therapy: by End User(USD Million)
  • Table 9. Immune Cell Therapy Hospitals , by Region USD Million (2016-2021)
  • Table 10. Immune Cell Therapy Cancer Research Centers , by Region USD Million (2016-2021)
  • Table 11. Immune Cell Therapy Clinics , by Region USD Million (2016-2021)
  • Table 12. South America Immune Cell Therapy, by Country USD Million (2016-2021)
  • Table 13. South America Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 14. South America Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 15. South America Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 16. Brazil Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 17. Brazil Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 18. Brazil Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 19. Argentina Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 20. Argentina Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 21. Argentina Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 22. Rest of South America Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 23. Rest of South America Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 24. Rest of South America Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 25. Asia Pacific Immune Cell Therapy, by Country USD Million (2016-2021)
  • Table 26. Asia Pacific Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 27. Asia Pacific Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 28. Asia Pacific Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 29. China Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 30. China Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 31. China Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 32. Japan Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 33. Japan Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 34. Japan Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 35. India Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 36. India Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 37. India Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 38. South Korea Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 39. South Korea Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 40. South Korea Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 41. Australia Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 42. Australia Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 43. Australia Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 44. Rest of Asia-Pacific Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 45. Rest of Asia-Pacific Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 47. Europe Immune Cell Therapy, by Country USD Million (2016-2021)
  • Table 48. Europe Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 49. Europe Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 50. Europe Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 51. Germany Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 52. Germany Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 53. Germany Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 54. France Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 55. France Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 56. France Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 57. Italy Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 58. Italy Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 59. Italy Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 60. United Kingdom Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 61. United Kingdom Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 62. United Kingdom Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 63. Netherlands Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 64. Netherlands Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 65. Netherlands Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 66. Rest of Europe Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 67. Rest of Europe Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 68. Rest of Europe Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 69. MEA Immune Cell Therapy, by Country USD Million (2016-2021)
  • Table 70. MEA Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 71. MEA Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 72. MEA Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 73. Middle East Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 74. Middle East Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 75. Middle East Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 76. Africa Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 77. Africa Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 78. Africa Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 79. North America Immune Cell Therapy, by Country USD Million (2016-2021)
  • Table 80. North America Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 81. North America Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 82. North America Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 83. United States Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 84. United States Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 85. United States Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 86. Canada Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 87. Canada Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 88. Canada Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 89. Mexico Immune Cell Therapy, by Application USD Million (2016-2021)
  • Table 90. Mexico Immune Cell Therapy, by Forms USD Million (2016-2021)
  • Table 91. Mexico Immune Cell Therapy, by End User USD Million (2016-2021)
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Immune Cell Therapy: by Application(USD Million)
  • Table 103. Immune Cell Therapy Cancer , by Region USD Million (2022-2027)
  • Table 104. Immune Cell Therapy Autoimmune Disease , by Region USD Million (2022-2027)
  • Table 105. Immune Cell Therapy Chronic Inflammation , by Region USD Million (2022-2027)
  • Table 106. Immune Cell Therapy: by Forms(USD Million)
  • Table 107. Immune Cell Therapy Nonspecific Immunotherapies , by Region USD Million (2022-2027)
  • Table 108. Immune Cell Therapy Cancer Vaccines , by Region USD Million (2022-2027)
  • Table 109. Immune Cell Therapy: by End User(USD Million)
  • Table 110. Immune Cell Therapy Hospitals , by Region USD Million (2022-2027)
  • Table 111. Immune Cell Therapy Cancer Research Centers , by Region USD Million (2022-2027)
  • Table 112. Immune Cell Therapy Clinics , by Region USD Million (2022-2027)
  • Table 113. South America Immune Cell Therapy, by Country USD Million (2022-2027)
  • Table 114. South America Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 115. South America Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 116. South America Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 117. Brazil Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 118. Brazil Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 119. Brazil Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 120. Argentina Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 121. Argentina Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 122. Argentina Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 123. Rest of South America Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 124. Rest of South America Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 125. Rest of South America Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 126. Asia Pacific Immune Cell Therapy, by Country USD Million (2022-2027)
  • Table 127. Asia Pacific Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 128. Asia Pacific Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 129. Asia Pacific Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 130. China Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 131. China Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 132. China Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 133. Japan Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 134. Japan Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 135. Japan Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 136. India Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 137. India Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 138. India Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 139. South Korea Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 140. South Korea Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 141. South Korea Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 142. Australia Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 143. Australia Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 144. Australia Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 145. Rest of Asia-Pacific Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 146. Rest of Asia-Pacific Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 147. Rest of Asia-Pacific Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 148. Europe Immune Cell Therapy, by Country USD Million (2022-2027)
  • Table 149. Europe Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 150. Europe Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 151. Europe Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 152. Germany Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 153. Germany Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 154. Germany Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 155. France Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 156. France Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 157. France Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 158. Italy Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 159. Italy Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 160. Italy Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 161. United Kingdom Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 162. United Kingdom Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 163. United Kingdom Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 164. Netherlands Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 165. Netherlands Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 166. Netherlands Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 167. Rest of Europe Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 168. Rest of Europe Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 169. Rest of Europe Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 170. MEA Immune Cell Therapy, by Country USD Million (2022-2027)
  • Table 171. MEA Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 172. MEA Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 173. MEA Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 174. Middle East Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 175. Middle East Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 176. Middle East Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 177. Africa Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 178. Africa Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 179. Africa Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 180. North America Immune Cell Therapy, by Country USD Million (2022-2027)
  • Table 181. North America Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 182. North America Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 183. North America Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 184. United States Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 185. United States Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 186. United States Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 187. Canada Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 188. Canada Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 189. Canada Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 190. Mexico Immune Cell Therapy, by Application USD Million (2022-2027)
  • Table 191. Mexico Immune Cell Therapy, by Forms USD Million (2022-2027)
  • Table 192. Mexico Immune Cell Therapy, by End User USD Million (2022-2027)
  • Table 193. Research Programs/Design for This Report
  • Table 194. Key Data Information from Secondary Sources
  • Table 195. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immune Cell Therapy: by Application USD Million (2016-2021)
  • Figure 5. Global Immune Cell Therapy: by Forms USD Million (2016-2021)
  • Figure 6. Global Immune Cell Therapy: by End User USD Million (2016-2021)
  • Figure 7. South America Immune Cell Therapy Share (%), by Country
  • Figure 8. Asia Pacific Immune Cell Therapy Share (%), by Country
  • Figure 9. Europe Immune Cell Therapy Share (%), by Country
  • Figure 10. MEA Immune Cell Therapy Share (%), by Country
  • Figure 11. North America Immune Cell Therapy Share (%), by Country
  • Figure 12. Global Immune Cell Therapy share by Players 2021 (%)
  • Figure 13. Global Immune Cell Therapy share by Players (Top 3) 2021(%)
  • Figure 14. Global Immune Cell Therapy share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 17. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 18. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 20. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Amgen Inc. (United States) Revenue: by Geography 2021
  • Figure 22. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 24. McKinsey & Company (United States) Revenue, Net Income and Gross profit
  • Figure 25. McKinsey & Company (United States) Revenue: by Geography 2021
  • Figure 26. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2021
  • Figure 28. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Gilead Sciences, Inc. (United States) Revenue: by Geography 2021
  • Figure 30. Noile-Immune Biotech (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Noile-Immune Biotech (Japan) Revenue: by Geography 2021
  • Figure 32. Juno Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 33. Juno Therapeutics (United States) Revenue: by Geography 2021
  • Figure 34. Bluebird Bio (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bluebird Bio (United States) Revenue: by Geography 2021
  • Figure 36. Global Immune Cell Therapy: by Application USD Million (2022-2027)
  • Figure 37. Global Immune Cell Therapy: by Forms USD Million (2022-2027)
  • Figure 38. Global Immune Cell Therapy: by End User USD Million (2022-2027)
  • Figure 39. South America Immune Cell Therapy Share (%), by Country
  • Figure 40. Asia Pacific Immune Cell Therapy Share (%), by Country
  • Figure 41. Europe Immune Cell Therapy Share (%), by Country
  • Figure 42. MEA Immune Cell Therapy Share (%), by Country
  • Figure 43. North America Immune Cell Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Johnson & Johnson (United States)
  • Pfizer Inc. (United States)
  • Amgen Inc. (United States)
  • Novartis AG (Switzerland)
  • McKinsey & Company (United States)
  • Bristol-Myers Squibb Company (United States)
  • Gilead Sciences, Inc. (United States)
  • Noile-Immune Biotech (Japan)
  • Juno Therapeutics (United States)
  • Bluebird Bio (United States)
Additional players considered in the study are as follows:
Fate Therapeutics (United States) , Legend Biotechnology Co., Ltd (United States) , Sorrento Therapeutics, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation